Sobi’s Orfadin® oral suspension granted European patent - Prometheus IP

February 9, 2016by prometheusip0

A drug named Orfadin® (nitisinone) an oral suspension formulation for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) has been granted a patent by the EPO. Hereditary Tyrosinaemia type-1 (HT-1) is a rare genetic disease affecting children. [More]

prometheusip

Prometheus IP is a leading intellectual property service enterprise offering competent and economic Intellectual Property Rights (IPR) solutions which include Patents, Designs, Copyrights and Trademarks.

Hyderabad
Prometheus Patent Services Pvt Ltd.
Plot No:438, SPR Arcade,
1st Floor, TNGO’s Colony Phase 2
Gachibowli, Hyderabad-500032
Telangana, India.
Our locationsWhere to find us?
https://www.prometheusip.com/wp-content/uploads/2020/01/footer-map.png
Get in touchPrometheus IP Social
Prometheus IPHeadquarters
Prometheus Patent Services Pvt Ltd.
Plot No:438, SPR Arcade,
1st Floor, TNGO’s Colony Phase 2
Gachibowli, Hyderabad-500032
Telangana, India.
Our locationsWhere to find us?
https://www.prometheusip.com/wp-content/uploads/2020/01/footer-map.png
Get in touchPrometheus IP Social

Copyright Prometheus IP. All rights reserved.

Copyright Prometheus IP. All rights reserved.